A Comprehensive Genetic and Mechanistic Analysis of the PrecisionLife Study Findings in ME/CFS and Fibromyalgia

Executive Summary

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, multi-systemic, and debilitating disease with a poorly understood etiology. Historically, traditional genetic research methods have failed to yield reproducible findings, leaving millions of patients without a biological explanation or a path to effective therapies. The PrecisionLife study represents a fundamental shift in this landscape by applying a novel combinatorial analytics platform to identify the first detailed and replicable genetic risk factors for ME/CFS.

This groundbreaking analysis identified 14 genes, organized into a multi-dimensional patient stratification model that sheds light on the condition's underlying biology. These genes cluster into key mechanistic areas: metabolic/mitochondrial dysfunction, host response and immune dysregulation, and neuroimmune and neurological pathways. The findings provide a robust, quantitative foundation for understanding the disease's drivers, with a reproducible predictive odds ratio of 8.9, a score that surpasses many established monogenic risk factors in other diseases.

Crucially, the study also identified a shared genetic driver with fibromyalgia, a frequently co-morbid condition. The *CLOCK* gene, a central regulator of circadian rhythms, was found to be a key overlapping genetic factor in a subgroup of patients diagnosed with both conditions. This discovery provides a direct mechanistic link for the shared symptoms of pain, fatigue, and sleep disturbance, suggesting a common pathogenic origin rooted in the disruption of the body's fundamental time-keeping system.

The immediate implications of these findings are profound. They validate a new paradigm for genetic research in complex diseases and offer a path toward precision medicine for ME/CFS. This includes the development of low-cost, non-invasive genotypic diagnostics to provide a definitive biological diagnosis, and the identification of a portfolio of novel drug targets and repurposing candidates for clinical trials, thereby accelerating the development of personalized treatments that address the specific mechanisms of a patient's disease.

1. Introduction: The Methodological Revolution in ME/CFS Genetics

1.1 The Enigma of ME/CFS Etiology

Myalgic encephalomyelitis/chronic fatigue syndrome is a massively debilitating chronic disease that impacts 0.2 to 0.4 percent of the global population, with an estimated 25 percent of affected individuals being housebound or bedbound. The condition is characterized by a diverse range of

symptoms, including profound fatigue, post-exertional malaise (PEM), chronic pain, cognitive impairment (often referred to as "brain fog"), and unrefreshing sleep. Despite decades of global research, there are no approved diagnostic tests or disease-modifying therapies, leaving patients to struggle for decades to manage their symptoms.

A major obstacle to understanding ME/CFS has been the failure of traditional genetic studies, such as Genome-Wide Association Studies (GWAS), to identify significant and replicable genetic findings. This is largely due to the clinical heterogeneity of the disease and its polygenic, multi-systemic nature. The core challenge lies in the fact that ME/CFS is not caused by a single, large-effect gene but rather by the complex interplay of numerous genes and other factors, an architecture that traditional single-marker analysis is not designed to detect. The lack of reproducible genetic evidence has perpetuated the misconception of ME/CFS as a psychosomatic illness, hindering scientific progress and access to effective care.

1.2 The Combinatorial Analysis Approach

The PrecisionLife study, conducted in collaboration with the Metrodora Foundation, overcame this historical barrier by employing a unique combinatorial analytics platform. This AI-led approach departs from the conventional GWAS method by analyzing the non-linear effects of interactions between multiple genes and exogenous factors, such as clinical and epidemiological data. Instead of searching for single genes with strong associations, it identifies complex combinations of genetic markers (known as "disease risk signatures") that collectively drive disease pathology. This methodology is uniquely capable of revealing the causal disease biology of complex chronic conditions, enabling the stratification of patient populations into distinct subgroups based on shared disease drivers and mechanisms. The platform's success in ME/CFS demonstrates its ability to capture the cumulative effect of many small-effect genes, providing a level of detail and mechanistic insight that was previously unattainable.

1.3 The Groundbreaking Findings

Applying this methodology to a cohort of 2,382 ME/CFS patients and 4,764 controls from the UK Biobank, PrecisionLife identified 84 validated disease signatures involving 199 unique single nucleotide polymorphisms (SNPs). The most remarkable aspect of this discovery is the predictive power of these signatures. When a patient's genotype was analyzed for the presence of these risk signatures, the analysis yielded a reproducible odds ratio of 8.9, a score that demonstrates a powerful and unexpected predictive capacity. For context, this measure of disease risk is superior to many established monogenic risk factors for other conditions, such as BRCA mutations in predicting breast cancer risk. This finding provides the first robust and replicable genetic evidence for ME/CFS, firmly establishing its biological basis and moving the field of research into a new era of precision medicine.

2. The 14 Genes: A Mechanistic Breakdown of ME/CFS Biology

The PrecisionLife study prioritized a core set of 14 genes, each with a specific single nucleotide polymorphism (SNP) and a proposed mechanism of action. These genes provide a detailed genetic blueprint for ME/CFS, offering a window into the biological drivers of its key symptoms. The identified genes can be functionally grouped to reveal a cohesive pathophysiological model

encompassing metabolic, immune, and neurological systems.

Table 1: The 14 PrecisionLife ME/CFS Genes

Gene Name	Associated SNP	PrecisionLife Functional Category	Known Biological Role/Function
AKAP1	rs3785477	Metabolic	Scaffolding protein that regulates mitochondrial energy production, respiration, and cell survival.
ATP9A	rs2904106	Metabolic	Phospholipid flippase involved in endosomal recycling and cellular transport.
CDON	rs73021223	Metabolic	Cell-surface receptor involved in myogenesis and cell-to-cell adhesion.
GPC5	rs16947234	Metabolic	A member of the glypican family of proteoglycans, involved in cell growth, division, and signal transduction.
INSR	rs59165976	Metabolic	Encodes the insulin receptor, crucial for glucose metabolism and cellular energy pathways.
S100PBP	rs41306603	Host Response	A protein that interacts with the S100 calcium-binding protein P, implicated in cell adhesion and tumor suppression.
SULF2	rs56218501	Host Response	An extracellular sulfatase that modulates the activity of growth factors and regulates tissue regeneration and inflammation.
PHACTR2	rs9403525	Host Response	Regulates actin cytoskeleton organization and is implicated in neurodegenerative

Gene Name	Associated SNP	PrecisionLife Functional Category	Known Biological Role/Function
			diseases.
USP6NL	rs2499908	Host Response	A GTPase-activating protein involved in membrane trafficking and endocytosis.
KCNB1	rs237475	Autoimmune	Encodes a subunit of a potassium channel (Kv2.1) essential for neuronal electrical signaling and brain function.
SLC15A4	rs2398428	Autoimmune	An endolysosomal transporter that is crucial for regulating innate immune responses and Type I interferon production.
TMEM232	rs58264436	Autoimmune	A transmembrane protein that promotes inflammatory responses via the NF-\kappaB and STAT3 signaling pathways.
CLOCK	rs6832769	Autoimmune	A core circadian rhythm gene that regulates the body's sleep-wake cycle and other daily physiological processes.
SLC6A11	rs2304725	Sleep Disturbance	A GABA transporter (GAT3) responsible for regulating the concentration of the inhibitory neurotransmitter GABA.

2.1 Genes Associated with Metabolic and Mitochondrial Dysfunction

Mitochondrial dysfunction is a leading hypothesis for the cause of post-exertional malaise (PEM) and profound fatigue in ME/CFS, as it directly impacts the body’s ability to produce energy. The PrecisionLife study identified several genes within this category that provide a clear mechanistic link between genetics and core symptoms.

The gene *AKAP1* (A-kinase anchoring protein 1) is a critical scaffolding protein that localizes protein kinase A (PKA) to the outer mitochondrial membrane. In this role, *AKAP1* is essential for regulating mitochondrial respiration and promoting cell survival, especially during periods of

high-energy demand. The PrecisionLife study explicitly links a genetic variant in *AKAP1* to a fatigue phenotype, specifically PEM. A genetic defect that impairs *AKAP1* function could compromise mitochondrial energy production, leading to a diminished capacity for ATP generation. This would explain why even minor physical or mental exertion causes a disproportionate and disabling worsening of symptoms in ME/CFS patients.
The *INSR* gene provides instructions for the insulin receptor, which is fundamental to regulating glucose metabolism and influencing a multitude of cellular functions. The study's identification of *INSR* is significant because it was also found to be significant in a prior ME/CFS study. Defects in the insulin receptor, even those that do not rise to the level of severe insulin resistance syndromes, could lead to impaired glucose uptake and utilization by cells throughout the body. This systemic energy deficit could manifest as the profound fatigue and cognitive impairment ("brain fog") that are hallmarks of the disease.
Other metabolic genes identified, such as *ATP9A*, *GPC5*, and *CDON*, contribute to a broader model of systemic dysfunction. *ATP9A* is a phospholipid flippase involved in recycling cellular components from endosomes to the plasma membrane, a process critical for nutrient transport and cell signaling. Dysregulation of this fundamental transport system could have far-reaching effects on cellular health and energy metabolism. *GPC5* and *CDON* are involved in cell adhesion and growth regulation. While seemingly disparate, their dysregulation could contribute to the multi-systemic nature of ME/CFS, affecting muscle development (myogenesis, in the case of *CDON*), and cellular signaling. Such a disruption could be a source of the chronic myalgia and widespread pain experienced by patients.

2.2 Genes Associated with Host Response and Immune Regulation

The post-viral onset of ME/CFS is a long-standing observation, and the condition is frequently associated with immune system abnormalities, including chronic inflammation and altered immune cell function. Several genes identified by PrecisionLife directly relate to these immunological pathways.
SLC15A4 is an endolysosomal transporter that plays a pivotal role in regulating innate immune responses, specifically by modulating Toll-like receptor signaling and the production of Type I interferons. A genetic variant in this gene could lead to an inappropriate or hyperactive immune response, potentially explaining the chronic inflammatory state observed in many ME/CFS patients. A similar role is seen in *TMEM232*, a transmembrane protein that has been shown to promote inflammatory responses through the nuclear factor-kappaB (NF-\kappaB) and signal transducer and activator of transcription 3 (STAT3) signaling pathways. Variants in these genes could predispose an individual to an unresolving inflammatory response following an infectious trigger, a hypothesis that aligns with the established clinical history of ME/CFS.
The remaining host response genes further complicate and clarify this picture. *S100PBP* is a protein that modulates cell adhesion, a process crucial for immune cell trafficking. *PHACTR2* and *USP6NL* are involved in cytoskeletal organization and intracellular membrane trafficking, respectively. Defects in these genes could impair immune cell mobility and communication. *SULF2* is an extracellular sulfatase that modulates growth factors and is involved in tissue regeneration and inflammation. The collective dysregulation of these genes suggests a complex, multi-layered breakdown in the host’s ability to respond to and recover from an infectious or inflammatory insult, leading to a persistent state of systemic disease.

2.3 Genes Associated with Neuroimmune and Neurological Pathways

The neurological symptoms of ME/CFS, including cognitive impairment, mood disorders, and autonomic nervous system dysfunction, are well-documented. The genetic findings offer a direct explanation for these symptoms by identifying genes that regulate neuronal function and neurotransmitter systems.

KCNB1 (potassium voltage-gated channel subfamily B member 1) provides instructions for a potassium channel essential for the generation and transmission of electrical signals in neurons. Pathogenic mutations in this gene are known to cause KCNB1 encephalopathy, a severe neurological disorder characterized by seizures, developmental delays, and brain dysfunction. While the variant identified in ME/CFS may not be as severe, its effect could be similar in principle: a subtle but persistent disruption of normal neuronal communication. This provides a direct mechanistic explanation for the “brain fog” and cognitive deficits experienced by patients, suggesting a physiological basis for these often-dismissed symptoms.

Another critical finding is the identification of *SLC6A11* as a key contributor to ME/CFS pathophysiology. *SLC6A11* encodes a sodium-dependent GABA transporter (GAT3) responsible for removing the inhibitory neurotransmitter GABA from the synaptic cleft, thereby terminating GABAergic neurotransmission. Dysregulation of this transporter could lead to an imbalance in inhibitory signaling in the brain, directly correlating with the symptoms of unrefreshing sleep, mood disturbances, and cognitive impairment reported by patients in this subgroup. This provides a clear neurochemical basis for several of the most challenging symptoms of ME/CFS.

3. Intersecting Pathologies: The Overlap with Fibromyalgia

Fibromyalgia (FM) is a chronic pain condition that shares a striking clinical overlap with ME/CFS, with common symptoms including widespread pain, fatigue, sleep disturbances, and cognitive dysfunction. The PrecisionLife study’s analysis of patient subgroups revealed a crucial genetic link between the two conditions: the *CLOCK* gene.

3.1 The CLOCK Gene: A Shared Genetic Driver

The study found that a specific subgroup of ME/CFS patients, who also had a fibromyalgia diagnosis, showed a genetic signature that included the *CLOCK* gene. This gene, whose name stands for "circadian locomotor output cycles kaput," is a core component of the molecular clock that regulates the body's 24-hour circadian rhythms. It is a central element of the transcription-translation feedback loop that governs daily fluctuations in physiological processes, including sleep-wake cycles, hormone secretion, and metabolism.

3.2 The Role of CLOCK in Circadian Rhythms, Pain, and Fatigue

The discovery of a shared genetic driver in *CLOCK* provides a powerful explanation for the overlapping symptomology of ME/CFS and fibromyalgia. Circadian rhythm disruption has long been suspected as a factor in both conditions, and the genetic finding provides a direct biological basis for this connection. A genetic variant in the *CLOCK* gene could lead to a fundamental misalignment of the body's internal clocks, disrupting the intricate timing of various bodily functions. This could directly contribute to unrefreshing sleep and chronic fatigue, which are defining features of both ME/CFS and FM.

Moreover, recent research provides a compelling mechanistic link between circadian rhythms

and the cardinal symptom of pain. Studies have shown that clock genes in nociceptors—the specialized sensory neurons that detect noxious stimuli—control excitability and modulate pain perception in a time-dependent manner. The disruption of a gene like *CLOCK* could therefore lead to a dysregulated pain-sensing system, where nociceptors are chronically in a state of heightened excitability, resulting in the widespread and constant dull ache characteristic of fibromyalgia.

While some studies have not found a significant difference in circadian rhythmicity between fibromyalgia patients and controls, this genetic finding offers a deeper level of understanding. The genetic variants identified by PrecisionLife do not necessarily dictate a specific observable rhythm but rather represent a predisposing factor that can make an individual's internal clocks more susceptible to misalignment under various stressors. The presence of this genetic driver in patients with a fibromyalgia diagnosis suggests that at least a subset of these cases originate from a shared defect in the body's fundamental time-keeping mechanism, a compelling hypothesis for these often-co-occurring conditions.

4. An Integrated Pathophysiological Model: From Genes to Syndrome

The genetic findings from the PrecisionLife study do not represent a collection of isolated facts but rather coalesce into a coherent, systems-level model of ME/CFS pathophysiology. This model can be conceptualized as a cascade of dysfunction across three interconnected systems: metabolic, immune, and neurological. A genetic predisposition in one area can initiate a series of downstream effects that contribute to the multi-systemic nature of the disease.

A proposed cascade begins with an underlying deficit in cellular energy. Variants in metabolic genes such as *AKAP1* or *INSR* could impair mitochondrial energy production or glucose utilization, creating a state of chronic cellular stress and energy debt. This stress can, in turn, trigger a chronic inflammatory response, which may be poorly regulated due to predisposing variants in immune-modulating genes like *SLC15A4* and *TMEM232*. The unresolving inflammation and immune activation then contribute to neuroinflammation and dysregulate neurological function. This is where genes like *KCNB1* and *SLC6A11* come into play, directly compromising neuronal communication and leading to the hallmark cognitive and neurological symptoms. Finally, the *CLOCK* gene can be viewed as an overarching upstream regulator, influencing the timing and function of all these systems, and thus providing a unifying explanation for the shared symptoms of ME/CFS and fibromyalgia.

This integrated model is supported by a clear correlation between the identified genes, their biological function, and the specific clinical symptoms of the disease.

Table 2: Gene-Symptom Correlation in the Integrated Model

Gene Name	Core Function	Proposed Mechanistic Link	Corresponding ME/CFS/Fibromyalgia Symptom(s)
AKAP1	Mitochondrial signaling hub	Impaired mitochondrial energy production.	Post-Exertional Malaise (PEM), profound fatigue.
INSR	Insulin signaling and	Reduced cellular	Chronic fatigue, "brain

Gene Name	Core Function	Proposed Mechanistic Link	Corresponding ME/CFS/Fibromyalgia Symptom(s)
	glucose metabolism	energy due to poor glucose utilization.	fog".
SULF2	Growth factor modulation	Dysregulated tissue repair and inflammatory signaling.	Persistent myalgia, inflammation, and pain.
SLC15A4	Endolysosomal immune signaling	Chronic, unresolving inflammatory response.	Post-viral onset, systemic inflammation, flu-like symptoms.
KCNB1	Neuronal potassium channel	Impaired neuronal electrical signaling and brain function.	Cognitive impairment ("brain fog"), autonomic dysfunction.
SLC6A11	GABA neurotransmitter transport	Disruption of inhibitory neurotransmission.	Unrefreshing sleep, mood disorders, cognitive deficits.
CLOCK	Circadian rhythm regulation	Misalignment of internal biological clocks.	Fatigue, sleep disturbance, widespread pain.

5. Conclusions and Future Implications for Precision Medicine

The PrecisionLife study has provided a new and solid foundation for understanding the biology of ME/CFS. By moving beyond the limitations of traditional genetic research, the combinatorial analytics platform has succeeded in identifying the first reproducible genetic associations for the disease. This achievement is not merely an academic exercise; it has immediate and profound implications for diagnosis and treatment.

The identification of these specific genetic signatures and their associated mechanisms opens the door for a new generation of precision diagnostics. PrecisionLife is already developing "mechanostic" genotypic tests that can identify a patient's disease risk and underlying biological drivers from a simple, low-cost sample. This offers the potential for earlier and more accurate diagnosis, providing clinicians with an objective, biological marker to support patient care and stratify individuals into homogeneous subgroups based on their specific disease mechanisms.

Furthermore, the research has identified novel drug targets and therapeutic opportunities. By linking genetic variants to specific biological pathways, the study points to existing drug candidates that can be repurposed to target a patient's underlying disease mechanism. This approach, which bypasses the long and costly process of de novo drug discovery, holds the potential to accelerate the approval of effective new personalized treatments for ME/CFS. Clinical trials are already underway to evaluate the safety and effectiveness of new diagnostics and potential drug repurposing candidates, a tangible sign of the progress being made.

In conclusion, the genetic findings from the PrecisionLife study provide a critical breakthrough in ME/CFS research. They validate the biological nature of the disease, offer a detailed roadmap for its pathophysiology, and pave the way for a future of precision medicine that promises to deliver accurate diagnostics and targeted treatments to a long-neglected patient population. Continued research to functionally validate these genes and their interactions is a crucial next

step toward fully realizing the promise of this groundbreaking work.

Works cited

1. Unraveling the Biological Drivers of ME and Long COVID ..., https://precisionlife.com/longcovid-mecfs 2. Identifying Genetic Risk Factors for ME/CFS and ... - PrecisionLife, https://precisionlife.com/hubfs/Poster%20-%20ME-CFS%20Long%20Covid%20-%20Identifying%20Genetic%20Risk%20Factors%20for%20MECFS%20and%20Long%20COVID%20-%20PrecisionLife%20Dec%202023.pdf?hsLang=en 3. Our science | PrecisionLife, https://precisionlife.com/innovation-engine 4. PrecisionLife and Metrodora Institute Launch ME/CFS and Long Covid Clinical Trials, https://precisionlife.com/news-and-events/precisionlife-and-metrodora-institute-launch-mecfs-clinical-trials 5. Myalgic encephalomyelitis/chronic fatigue syndrome - Wikipedia, https://en.wikipedia.org/wiki/Myalgic_encephalomyelitis/chronic_fatigue_syndrome 6. PrecisionLife identifies first detailed genetic risk factors for long ..., https://firstwordpharma.com/story/5762266 7. The Relationship Between Chronic Fatigue & Mitochondrial Health, https://www.ifm.org/articles/chronic-fatigue-and-mitochondrial-health 8. MITOCHONDRIA: A kinase anchoring protein 1, a signaling platform for mitochondrial form and function - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3940257/ 9. A-Kinase Anchoring Protein 1: Emerging Roles in Regulating Mitochondrial Form and Function in Health and Disease - MDPI, https://www.mdpi.com/2073-4409/9/2/298 10. INSR gene - MedlinePlus, https://medlineplus.gov/download/genetics/gene/insr.pdf 11. INSR gene: MedlinePlus Genetics, https://medlineplus.gov/genetics/gene/insr/ 12. pmc.ncbi.nlm.nih.gov, https://pmc.ncbi.nlm.nih.gov/articles/PMC5170610/#:~:text=We%20found%20that%20ATP9A%20plays,endosomes%20to%20the%20Golgi%20complex. 13. ATP9A ATPase phospholipid transporting 9A (putative) [(human)] - NCBI, https://www.ncbi.nlm.nih.gov/gene/10079 14. 50937 - Gene ResultCDON cell adhesion associated, oncogene regulated [(human)] - NCBI, https://www.ncbi.nlm.nih.gov/gene/50937 15. Cdon is essential for organ left-right patterning by regulating dorsal forerunner cells clustering and Kupffer's vesicle morphogenesis - Frontiers, https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1429782/full 16. www.ncbi.nlm.nih.gov, https://www.ncbi.nlm.nih.gov/gene/642987#:~:text=TMEM232%20promotes%20the%20inflammatory%20response,dermatitis%20through%20targeted%20capture%20sequencing. 17. GPC5 Gene and Its Related Pathways in Lung Cancer - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC3020075/ 18. Key genetic differences found in people with ME/CFS | News | The University of Edinburgh, https://www.ed.ac.uk/news/key-genetic-differences-found-in-people-with-mecfs 19. 121260 - Gene ResultSLC15A4 solute carrier family 15 member 4 [(human)] - NCBI, https://www.ncbi.nlm.nih.gov/gene/121260 20. Slc15a4 solute carrier family 15, member 4 [(house mouse)] - NCBI, https://www.ncbi.nlm.nih.gov/gene/100561 21. Immune cell metabolism altered in ME/CFS - National Institutes of Health (NIH) |, https://www.nih.gov/news-events/nih-research-matters/immune-cell-metabolism-altered-me-cfs 22. Inflammation of the brain - ME Research UK, https://www.meresearch.org.uk/inflammation-brain/ 23. The Neuroinflammatory Etiopathology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - Frontiers, https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2017.00088/full 24. TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-κB

and signal transducer and activator of transcription 3 signalling pathways - PubMed, https://pubmed.ncbi.nlm.nih.gov/36928730/ 25. S100PBP Gene - Ma'ayan Laboratory, Computational Systems Biology, https://maayanlab.cloud/Harmonizome/gene/S100PBP 26. S100PBP Gene - S100P Binding Protein - GeneCards, https://www.genecards.org/cgi-bin/carddisp.pl?gene=S100PBP 27. PHACTR2 Gene - Ma'ayan Laboratory, Computational Systems Biology, https://maayanlab.cloud/Harmonizome/gene/PHACTR2 28. USP6NL - USP6 N-terminal-like protein - Homo sapiens (Human) | UniProtKB | UniProt, https://www.uniprot.org/uniprotkb/Q92738/entry 29. 72043 - Gene ResultSulf2 sulfatase 2 [(house mouse)] - NCBI, https://www.ncbi.nlm.nih.gov/gene/72043 30. medlineplus.gov, https://medlineplus.gov/genetics/condition/kcnb1-encephalopathy/#:~:text=The%20KCNB1%20gene%20provides%20instructions,generate%20and%20transmit%20electrical%20signals. 31. KCNB1 gene: MedlinePlus Genetics, https://medlineplus.gov/genetics/gene/kcnb1/ 32. rarediseases.org, https://rarediseases.org/rare-diseases/kcnb1-encephalopathy/#:~:text=Disease%20Overview&text=KCNB1%20encephalopathy%20is%20a%20rare,to%20control%20with%20standard%20treatments. 33. KCNB1 encephalopathy: MedlinePlus Genetics, https://medlineplus.gov/genetics/condition/kcnb1-encephalopathy/ 34. 6538 - Gene ResultSLC6A11 solute carrier family 6 member 11 [(human)] - NCBI, https://www.ncbi.nlm.nih.gov/gene/6538 35. GABA transporter subfamily - IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=177 36. Fibromyalgia - Symptoms & causes - Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/fibromyalgia/symptoms-causes/syc-20354780 37. Circadian Rhythms and Pain - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC8429267/ 38. Circadian rhythm disruption in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for the post-acute sequelae of COVID-19 - ResearchGate, https://www.researchgate.net/publication/357703972_Circadian_rhythm_disruption_in_Myalgic_EncephalomyelitisChronic_Fatigue_Syndrome_Implications_for_the_post-acute_sequelae_of_COVID-19 39. Circadian Rhythms of Women with Fibromyalgia1 | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, https://academic.oup.com/jcem/article-abstract/86/3/1034/2847502 40. Nociceptor clock genes control excitability and pain perception in a ..., https://www.biorxiv.org/content/10.1101/2025.04.07.646998v1